Jefferies Financial Group Inc. Invests $6.27 Million in Axsome Therapeutics, Inc. $AXSM

Jefferies Financial Group Inc. acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 25,628 shares of the company’s stock, valued at approximately $6,273,000.

Several other hedge funds also recently made changes to their positions in AXSM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of Axsome Therapeutics by 2,407.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after buying an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Axsome Therapeutics by 38.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after buying an additional 84,151 shares during the period. Caxton Associates LLP bought a new stake in shares of Axsome Therapeutics during the 1st quarter valued at about $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,250 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $199.02 on Friday. The stock’s fifty day simple moving average is $227.43 and its 200 day simple moving average is $206.72. The stock has a market capitalization of $10.42 billion, a price-to-earnings ratio of -53.07 and a beta of 0.65. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. Axsome Therapeutics, Inc. has a 52-week low of $112.90 and a 52-week high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). The company had revenue of $218.38 million during the quarter, compared to analyst estimates of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. As a group, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Royal Bank Of Canada dropped their price target on Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. BMO Capital Markets started coverage on shares of Axsome Therapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $310.00 price target for the company. Truist Financial upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. Wells Fargo & Company raised their price target on shares of Axsome Therapeutics from $255.00 to $256.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, Oppenheimer set a $280.00 price objective on Axsome Therapeutics in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $267.60.

Insider Buying and Selling at Axsome Therapeutics

In related news, Director Mark Coleman sold 643 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the sale, the director directly owned 30,389 shares in the company, valued at approximately $7,566,861. This trade represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Herriot Tabuteau sold 4,660 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total value of $997,007.00. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This trade represents a 39.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 194,766 shares of company stock valued at $45,284,886 over the last three months. 20.60% of the stock is owned by insiders.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.